多中心多试验队列分析:淋巴瘤CAR-T疗效应答的决定因素
该研究分析580例非霍奇金淋巴瘤患者接受axi-cel治疗的多个临床试验长期随访数据,发现产品中naive-like(CCR7+CD45RA+)T细胞比例高与无进展生存期延长显著相关(HR=0.46),且不增加安全性风险,该关联独立于肿瘤微环境并在独立队列中验证。
要点
- 产品中naive-like T细胞比例高与PFS延长显著相关(HR=0.46)。
- naive-like T细胞比例与疗效的关系独立于肿瘤微环境特征。
- 既往治疗线数与naive-like T细胞比例呈负相关,提示早期干预可能获益。
核心结论
- 抗CD19 CAR-T产品中naive-like T细胞比例高是与PFS延长最显著相关的特征,且不影响安全性。
研究设计与样本
- 分析580例非霍奇金淋巴瘤患者接受axi-cel治疗的多个临床试验长期随访数据(中位随访41.9个月)。
- 肿瘤微环境特征在112例患者中评估。
- 关键发现在203例接受axi-cel为基础治疗或brexucabtagene autoleucel治疗的独立队列中验证。
- 对116例患者产品进行飞行时间质谱流式分析。
主要发现
- naive-like T细胞高组对比低组的PFS风险比为0.46(95%CI:0.31-0.68,P=9.8×10^-5)。
- naive-like T细胞与疗效的关系独立于肿瘤微环境特征。
- 多变量模型中naive-like表型优于炎症标志物和肿瘤负荷等临床病理特征,调整产品扩增后仍显著。
- 既往治疗线数与产品及匹配单采样本中naive-like T细胞比例呈负相关。
- 缺乏TIGIT、LAG-3和PD-1等耗竭标志物表达的CD8 naive-like T细胞表型与PFS相关。
临床怎么用
- 评估CAR-T产品中naive-like T细胞比例可能有助于预测疗效。
- 考虑在更早治疗线数采集T细胞可能提高产品中naive-like T细胞比例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with non-Hodgkin lymphoma (NHL) treated with chimeric antigen receptor (CAR) T cell therapy, factors associated with efficacy overlap with prognostic biomarkers. Currently, there is no consensus on optimal product characteristics. We analyzed the phenotypic attributes of the anti-CD19 CAR T therapy axicabtagene ciloleucel (axi-cel) from 580 patients with NHL across multiple clinical trials with long-term follow-up (median, 41.9 months). A high proportion of naive-like (CCR7+CD45RA+) T cells was the most significant feature associated with prolonged progression-free survival (PFS; hazard ratio = 0.46, 95% confidence interval: 0.31-0.68, P = 9.8 × 10-5, high versus low naive-like T cell groups) without impacting safety. The relationship between naive-like T cells and efficacy was independent of tumor microenvironment characteristics (assessed in 112 patients). In multivariate models, the naive-like phenotype outperformed clinicopathologic features such as inflammatory markers and tumor burden, remaining significant after adjusting for product expansion. An inverse correlation was observed between prior lines of therapy and the proportion of naive-like T cells in both product and matched apheresis samples, suggesting a benefit of earlier intervention. The key findings were validated in an independent cohort of 203 patients treated with axi-cel-based therapy or brexucabtagene autoleucel. Mass cytometry by time-of-flight analysis of products from a subgroup of 116 patients confirmed an association between a CD8 naive-like T cell phenotype lacking expression of exhaustion markers, such as TIGIT, LAG-3 and PD-1, and PFS. The evidence generated by this study has the potential to advance the development of more effective cellular therapies.
引用
- Budka J, Davis M, Cao S, et al. Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma. Nat Med. 2026. PMID: 42919964. doi:10.1038/s41591-026-04707-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。